We read with great interest the recent paper by Schuierer et al., who conclude that acyclovir treatment was associated with a significantly longer time to death in the intensive care unit (ICU), reduced hazard ratio for ICU death, and improved circulatory and pulmonary oxygenation function in patients with ventilator-associated pneumonia (VAP) not responding to antibiotic treatment and with high herpes simplex virus (HSV) load. They suggest testing all patients with a diagnosis of antibiotic refractory VAP for HSV replication in respiratory secretions and considering acyclovir treatment if more than 105 copies/mL are detected [1]. We would like to make some comments. First, this area remains controversial as several prospective studies have failed to show an increase in mortality associated with HSV infection [2] and the only prospective therapeutic study is limited by small sample size and prophylactic (rather than treatment) dosing [3]. Also, as clinicians, we need to take into account the side effects of the drugs we prescribe and indeed acyclovir is not a benign drug. Nephrotoxicity is the most important side effect of acyclovir, with an overall incidence of AKI of 13%, half of which are KDIGO grade 2/3 [4]. AKI has been found to occur more frequently in patients with pre-existing chronic kidney disease (CKD), diabetes, and in patients treated with higher daily doses of acyclovir [4]. Despite its importance, the acyclovir dose that patients received was not reported in this study [1]. Furthermore, for a study of a drug with known renal toxicity, there is a striking paucity of information regarding renal parameters. There is an upward trend in the incidence of dialysis in those receiving acyclovir, though the difference was not statistically significant, perhaps due to the small number of patients [1]. It should also be noted that acyclovir may be more toxic if given in conjunction with some antibiotics, such as was the case in this study [1]. In a recent study looking at acyclovir-associated AKI, multivariate analysis indicated that the presence of diabetes, concomitant non-steroidal anti-inflammatory drugs (NSAIDs), and vancomycin use were independent risk factors for acyclovir-associated AKI, and higher mortality was observed in AKI patients [5]. Nephrotoxicity associated with IV acyclovir is common and necessitates renal function monitoring. Randomised control trials with more comprehensive data on dose and renal parameters are needed before recommendations regarding acyclovir treatment in the setting of VAP can be made.
Authors’ response
Reinhard Hoffmann2,3, Lukas Schuierer1,2,3
Anzeige
1. TUM Graduate School, Technical University of Munich (TUM), Germany
2. Institute for Laboratory Medicine and Microbiology, University Hospital Augsburg, Germany
3. Faculty of Medicine, Augsburg University, Germany
We appreciate the interest of professor Honore and colleagues in our recent publication and thank for their qualified comments.
Anzeige
First, we totally agree that the subject remains controversial and that larger, prospectively randomised trials are needed. To complete our picture, we re-analysed the data and compared 30-day-mortality in our patient cohort. We could confirm our findings by demonstrating that acyclovir significantly reduced 30-day-mortality in high load patients, only (Table 1). Thus, in the absence of higher quality data, we think that our study may add a small but significant piece to the larger puzzle and may aid clinicians in specific situations.
Table 1
Evaluation of 30-day mortality
All patients | Low viral load (103-105 copies/mL) | High viral load (>105 copies/mL) | |||||||
|---|---|---|---|---|---|---|---|---|---|
Untreated n = 24 | Treated n = 65 | p | Untreated n = 14 | Treated n = 16 | p | Untreated n = 10 | Treated n = 49 | p | |
30-day mortality | 14 (58%) | 27 (42%) | 0.231 | 6 (43%) | 6 (38%) | 1 | 8 (80%) | 21 (43%) | 0.042 |
Next, we also agree that possible side effects have to be considered before prescribing any drug to any ICU patient. Therefore, we strictly focused on patients with a high likelihood of viral disease. In our cohort, a maximum dose of 9 mg/kg [median, IQR 7–11] was administered three times daily. Total acyclovir treatment duration of surviving patients was 10 days [median, IQR 6.5–14]. The decision to treat patients with parenteral acyclovir and possible dose reductions in response to worsening renal function was left to the treating clinicians. Table 2 shows the daily acyclovir doses and important renal parameters over the course of antiviral treatment. If at all, only a slight decrease in daily urine volume and a slight increase in the number of patients with estimated GFR < 60 ml/min/1.73 m2 and a slight increase in creatinine values are evident. We suggest that antiviral treatment may have an impact on renal function, but at least in our cohort, this is not clinically significant.
Table 2
Renal function of antivirally treated patients (n = 59)
Antiviral treatment | Daily dose of aciclovir (mg) | Daily urine volume (ml) | Estimated GFR <60 ml/min/1.73m2 | Serum creatine (mg/dl) |
|---|---|---|---|---|
Day 0 | 1000 [750 -1500]; n = 58 | 2300 [1550-3175]; n = 59 | 41.1 [21.1-50.1]; n = 19 | 1.01 [0.66-1.23]; n = 55 |
Day 1 | 2250 [1500-2250]; n = 58 | 2700 [1800-3600]; n = 59 | 40.5 [22.4-47.3]; n = 22 | 0.93 [0.67-1.39]; n = 57 |
Day 2 | 2100 [1400-2250]; n = 57 | 2404 [1435-3438]; n = 58 | 44.7 [27.8-51.7]; n = 25 | 1.04 [0.68-1.35]; n = 57 |
Day 3 | 1850 [1150-2250]; n = 52 | 2620 [1390-3813]; n = 52 | 41.6 [31.7-47.4]; n = 22 | 0.96 [0.65-1.50]; n = 51 |
Day 4 | 2000 [1000-2250]; n = 45 | 2900 [2000-3350]; n = 45 | 40.3 [20.3-45.2]; n = 17 | 0.97 [0.69-1.42]; n = 44 |
Day 5 | 2000 [1260-2250]; n = 36 | 3220 [2075-4293]; n = 36 | 41.3 [38.4-50.1]; n = 17 | 1.04 [0.67-1.46]; n = 37 |
Day 6 | 2250 [1500-2250]; n = 34 | 2725 [1928-3868]; n = 34 | 42.0 [39.5-48.0]; n = 14 | 0.97 [0.66-1.44]; n = 33 |
Day 7 | 2125 [1500-2250]; n = 30 | 2800 [2075-4075]; n = 30 | 42.3 [37.8-48.8]; n = 12 | 0.84 [0.62-1.35]; n = 31 |
This is well in line with published data. In a recently published trial, IV acyclovir treatment at 5 mg/kg TID was considered safe, with no difference in renal failure, creatinine increase, and renal replacement therapy rates compared to the placebo group [6]. Richelsen et al. described nephrotoxicity in 5.1–10.5% of patients receiving 10 mg/kg acyclovir TID, which was fully reversible [7]. Moreover, older studies already showed that nephrotoxicity was usually reversible and could be minimised by slow infusion and adequate hydration [8]. Thus, we fully agree that the administration of high acyclovir doses may impose some risk of renal failure, which has to be weighed against the probable survival benefit in patients with otherwise unexplained VAP and high HSV load in the lower respiratory tract.
Sincerely,
Reinhard Hoffmann
Lukas Schuierer
Acknowledgements
We would like to thank Dr. Melissa Jackson for the critical review of the manuscript.
Ethics approval and consent to participate
Not applicable.
Anzeige
Consent for publication
Not applicable.
Competing interests
The authors declare to have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.